Saratoga Health & Biotechnology Portfolio Fund Class Institutional (SBHIX)

Fund Assets	12.04M
Expense Ratio	2.53%
Min. Investment	$250
Turnover	22.00%
Dividend (ttm)	n/a
Dividend Yield	n/a
Dividend Growth	n/a
Payout Frequency	Annual
Ex-Dividend Date	Dec 9, 2025

Previous Close	30.74
YTD Return	18.99%
1-Year Return	24.43%
5-Year Return	48.09%
52-Week Low	24.95
52-Week High	31.56
Beta (5Y)	0.52
Holdings	29
Inception Date	Jan 27, 2003

About SBHIX

Saratoga Health & Biotechnology Portfolio Fund Class I is a mutual fund focused on the healthcare and biotechnology sectors. Its primary objective is to achieve long-term capital growth by investing at least 80% of its assets in equity securities of U.S. and foreign companies that are actively engaged in health care, health products, pharmaceuticals, and biotechnology industries. The fund’s portfolio typically includes a diverse selection of companies ranging from pharmaceutical developers to providers of medical technologies and health services. Notable features include a relatively concentrated portfolio, with around 45% of assets allocated to its top ten holdings, reflecting an emphasis on select high-impact companies in the sector. The fund is intended for investors seeking exposure to the dynamic healthcare and biotech markets, and it has an institutional share class with a minimum investment of $250. Although the fund has historically provided competitive long-term returns, it carries a higher expense ratio compared to peers, reflecting the active management involved in sector-specific research and selection. Saratoga Health & Biotechnology Portfolio Fund Class I plays a specialized role in the financial market, catering to those interested in the growth potential and innovation within the health and biotechnology fields.

• Fund Family: Saratoga
• Category: Health
• Performance Rating: Average
• Risk Rating: Below Average
• Stock Exchange: Nasdaq
• Ticker Symbol: SBHIX
• Share Class: Class I
• Index: S&P 500 TR

Performance

SBHIX had a total return of 24.43% in the past year, including dividends. Since the fund's inception, the average annual return has been 8.95%.

Equivalent Funds

These are funds that follow the same index from the other major fund companies.

Symbol	Provider	Name	Expense Ratio
FACDX	Fidelity	Fidelity Advisor Health Care A	0.92%
FACTX	Fidelity	Fidelity Advisor Health Care M	1.23%
FBIOX	Fidelity	Fidelity Select Biotechnology Portfolio	0.60%
FBTAX	Fidelity	Fidelity Advisor Biotechnology A	0.95%
FBTCX	Fidelity	Fidelity Advisor Biotechnology C	1.65%

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

Symbol	Share Class	Expense Ratio
SHPAX	Class A	3.00%
SHPCX	Health & Biotechnology Porfolio Class C	3.60%

Top 10 Holdings

50.39% of assets

Name	Symbol	Weight
Amgen Inc.	AMGN	5.93%
Jazz Pharmaceuticals plc	JAZZ	5.69%
United Therapeutics Corporation	UTHR	5.64%
McKesson Corporation	MCK	5.29%
Cardinal Health, Inc.	CAH	5.05%
Exelixis, Inc.	EXEL	4.95%
Regeneron Pharmaceuticals, Inc.	REGN	4.56%
Cencora, Inc.	COR	4.53%
Medpace Holdings, Inc.	MEDP	4.42%
Johnson & Johnson	JNJ	4.32%

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 9, 2025	$0.7788	Dec 10, 2025
Dec 10, 2024	$0.2534	Dec 11, 2024
Dec 8, 2023	$1.0202	Dec 11, 2023
Dec 9, 2022	$1.2749	Dec 12, 2022
Dec 10, 2021	$0.7883	Dec 13, 2021
Dec 11, 2020	$2.5794	Dec 11, 2020

Data Sources: Tiingo, Twelve Data, and more

Historical data is provided by Tiingo. Delayed stock pricing data is provided by Twelve Data. Several fund data points are also provided by Finnhub.

Last checked:

Nov 9, 2026

Data Sources Report a data error